T
Tina Cheng
Researcher at University of Calgary
Publications - 40
Citations - 6479
Tina Cheng is an academic researcher from University of Calgary. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 13, co-authored 28 publications receiving 5642 citations. Previous affiliations of Tina Cheng include Tom Baker Cancer Centre & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng,Wanling Xie,Meredith M. Regan,Mark Andrew Warren,Ali Reza Golshayan,Chakshu Sahi,Bernhard J. Eigl,J. Dean Ruether,Tina Cheng,Scott North,Peter Venner,Jennifer J. Knox,Kim N. Chi,Christian Kollmannsberger,David F. McDermott,William Oh,Michael B. Atkins,Ronald M. Bukowski,Brian I. Rini,Toni K. Choueiri +19 more
TL;DR: This model validates components of the MSKCC model with the addition of platelet and neutrophil counts and can be incorporated into patient care and into clinical trials that use VEGF-targeted agents.
Journal ArticleDOI
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
Leila Khoja,Leila Khoja,Eshetu G. Atenafu,Stefan Suciu,Serge Leyvraz,Takami Sato,Ernie Marshall,Ulrich Keilholz,Lisa Zimmer,Sandip Pravin Patel,Sophie Piperno-Neumann,Josep M. Piulats,Tero Kivelä,Claudia Pfoehler,Shailender Bhatia,P. Huppert,L. B. J. Van Iersel,L. de Vries,Nicolas Penel,T. Vogl,Tina Cheng,G. Fiorentini,Frédéric Mouriaux,Ahmad A. Tarhini,Poulam M. Patel,Richard D. Carvajal,Anthony M. Joshua,Anthony M. Joshua +27 more
TL;DR: In this paper, a meta-analysis using individual patient level trial data was performed to determine benchmarks of progression free survival (PFS) and overall survival (OS) for metastatic uveal melanoma (mUM).
Journal ArticleDOI
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Tina Cheng,Peter A. Forsyth,Ahsan Chaudhry,Don Morris,Stefan Glück,James A. Russell,D A Stewart +6 more
TL;DR: It is suggested that high-dose chemotherapy for PCNSL should include drugs that penetrate the CNS such as busulfan and thiotepa rather than standard lymphoma regimens such as BEAM.
Journal ArticleDOI
Canadian consensus guidelines for the management of testicular germ cell cancer.
Lori Wood,Christian Kollmannsberger,Michael A.S. Jewett,Peter Chung,S.J. Hotte,Martin E. O’Malley,Joan Sweet,Lynn Anson-Cartwright,Eric Winquist,Scott North,Scott Tyldesley,Jeremy Sturgeon,Mary Gospodarowicz,Roanne J. Segal,Tina Cheng,Peter Venner,Malcolm J. Moore,Peter Albers,Robert Huddart,Craig R. Nichols,Padraig Warde +20 more
TL;DR: This Canadian Consensus Guideline covers many aspects of the diagnosis and management of germ cell cancer, and is of considerable importance that clear, comprehensive and up-to-date consensus guidelines are available.